Medulloblastoma (MB) is the second most common pediatric primary brain tumor (after astrocytoma), accounting for 16% - 18% of the subtypes (
1,
2). It is more common in males (M:F 1.2:1) and typically presents between 5 and 7 years of age (
1-
3). It is one of the embryonal and neuroblastic tumors and was previously known as primitive neuroectodermal tumor (PNET) of the cerebellum.
MB is typically situated in the posterior fossa (infratentorial). It arises in the midline of the cerebellum and usually obstructs the fourth ventricle resulting in obstructive hydrocephalus (
4,
5). Thus, the typical clinical presentation is that of raised intracranial pressure (ICP), including headache, and vomiting. It will also cause cerebellar dysfunction resulting in ataxia or gait abnormalities. Our patient did not have symptoms of raised ICP at presentation. What brought him to the hospital initially was falling from the staircase. However, it is important and interesting to note that it was not the fall but rather the symptom of right partial ptosis and blurred vision that prompted a referral to the ophthalmology unit at a tertiary referral center. The ptosis may be explained by the location of the tumor where it compresses the right midbrain tegmentum. The right midbrain tegmentum has the nucleus and fascicles of the oculomotor nerve (cranial nerve III) (
6). The tumor also extended beyond the posterior fossa into the cavernous sinus and suprasellar region, possibly compressing the oculomotor nerve as it passed through the cavernous sinus. Further history from the patient’s father also revealed a two-week history of poor coordination and frequent falls, which may be attributed to the cerebellar location of the lesion.
Another interesting point about this tumor is its location. Classic medulloblastomas (CMB) are infratentorial and located midline within the fourth ventricle (
4). In this patient, the tumor arises from the right pons and midbrain (infratentorial but off midline), and also extends supratentorially into the cavernous sinus and suprasellar region. The fourth ventricle is compressed but is otherwise spared from tumor infiltration. As described above, this attributes to the atypical presentation of the patient. Expansion of the tumor into the supratentorial compartment may be metastatic in nature secondary to cerebrospinal fluid (CSF) dissemination (
4,
7). This tumor also extends into the right cerebellopontine angle which is rare in MBs (
4).
Histologically, MBs can be divided into three subtypes; desmoplastic/nodular MB, classical MB, and anaplastic/large cell MB (high grade) (
4,
8,
9). Classical MB is typically hypointense on T1W and hyperintense on T2W with restricted diffusion and variable enhancement (
4). Anaplastic MB is associated with increased apparent diffusion coefficient (ADC) value and ring enhancement (
10).
In addition, this tumor could also be typed according to four molecular subgroups based on the predominant mutation driving the tumor pathogenesis. They are: Shh, Wnt, Group 3 (having principally MYC mutation), and Group 4 (mutation in isochromosome 17q) MBs (
11). The groups have distinct clinicopathological features. The first two groups are better characterized compared to the latter two groups, which is why the latter groups have generic names. Several authors have tried to describe the typical radiological features of the tumor subtypes. Although there is no general consensus yet, most authors described the tumor’s location as its predominant feature.
Shh MB arises from granule neuron precursor cells (GNPCs) as a result of an unrestrained Shh pathway. It accounts for 25% - 30% of the MBs and has a bimodal age distribution. On imaging, the tumor is typically located in the body of the cerebellum, lateralizing to the sides of the organ (
4,
12,
13). Raleigh et al. also described the tumor as typically isointense on T2-FLAIR sequence (
14).
The other three molecular subtypes of MB are typically situated in the midline (
13). Wnt MB is the smallest subgroup (10%) and typically arises from the dorsal brainstem and fourth ventricle as a result of activation of the WNT pathway, vital in tumor growth. It could also extend to the cerebello-pontine angle (CPA) (
12). Wnt MB has the best prognosis with standard therapy. Group 3 accounts for 25% of the MBs and has the worst prognosis. It is typically ill defined with ring enhancement and central necrosis. Group 4 medulloblastoma is the largest group (35%). It typically arises from the fourth ventricle. It is associated with minimal to no enhancement (
4,
11,
14,
15).
Our patient had the classical MB type on histopathology, and the tumor is possibly of the Shh molecular subgroup as it arises from the dorsal brain stem rather than the fourth ventricle. Another point to ponder is whether the tumor is an intracranial PNET, arising from the anterior cranial fossa and spreading posteriorly. The immunohistochemical and molecular patterns are similar for both PNET and MB, making differentiating the two an arduous task. However, the almost equal tumor distribution between the suprasellar area and the posterior cranial fossa on imaging studies, and presence of spinal drop metastases supports the diagnosis of MB rather than PNET. Furthermore, MB is the most common childhood intracranial tumor. Fortunately, both tumors respond to the same treatment, making the importance of differentiating them of less urgency compared to if otherwise.
Standard therapy for MBs involve surgical resection followed by adjuvant chemotherapy or craniospinal irradiation. Following the discovery of Shh pathways, targeted therapies utilizing small molecule inhibitors to smoothened (SMO), which is part of the Shh pathway, have been developed. Inhibitors of GNPCs proliferation are also being developed. However, at this point, the prognosis for patients with sonic hedgehog (SHH) MBs is still relatively poor. In contrast to SHH MBs, few drugs are developed to target the wingless (WNT) pathway. With standard therapy, Wnt MBs has the best prognosis (
11,
15).
In conclusion, although MB is a common pediatric tumor, suprasellar extension of MB is very rare and may cause atypical presentations.